4D Molecular Therapeutics announced positive two-year results from its PRISM Phase 2b trial of 4D-150, a gene therapy for wet age-related macular degeneration (wet AMD). The trial showed that a single dose maintained visual acuity and anatomical control while significantly reducing the need for additional injections by up to 87% in recently diagnosed patients. The therapy was well tolerated with minimal inflammation and no serious adverse effects over two years. These results support ongoing Phase 3 trials and highlight 4D-150's potential to reduce treatment burden and improve long-term vision outcomes for wet AMD patients.
Meta, led by Mark Zuckerberg, plans to begin production of its in-house Iris AI chip in September. This move is part of Meta's strategy to double its computing capacity to 14 gigawatts, enhancing its AI and data processing capabilities. The new chip ...
Solana's price is stabilizing near the crucial $74 support level as selling pressure from the meme-coin launchpad Pump.fun offsets growing demand driven by USDC stablecoin inflows and tokenized real-world assets (RWA). Pump.fun has been a significant...
Quanta Services is transforming from a traditional construction contractor into a capacity brokerage firm, leveraging its integrated platform and expanding transformer capacity to secure long-term, high-value infrastructure projects. The company’s 20...
XRP is approaching a key technical breakout point amid positive regulatory progress in Europe with Ripple gaining approval under the EU's MiCA framework, allowing broader crypto services across 30 countries. However, uncertainty remains in the US due...
Robinhood Chain launched in July 2026 and quickly saw a memecoin-driven DEX volume surge over $3 billion, briefly ranking it among top decentralized exchanges. However, Solana outpaces Robinhood by a wide margin with roughly $4.93 billion in value lo...
